Adalimumab biosimilar (Oncobiologics)

阿达木单抗生物类似药（Oncobiologics）

Report date: 2026/04/01 10:49:23

Base Information

Drug NameAdalimumab biosimilar (Oncobiologics)
Drug Alias Name阿达木单抗生物仿制药（Oncobiologics）Adalimumab (Oncobiologics)Adalimumabum (Oncobiologics)阿达利木单抗生物仿制药（Oncobiologics）闲康乐 +[8] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPlaque psoriasisPsoriasisUveitis +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesOutlook Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Huahai Biological Technology Co LtdOutlook Therapeutics IncShanghai Huaota Biopharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisUveitis +[8] 
Inactive IndicationsArthritis

Other Information

ATC CodeL04AB04
Related LinksN/A